Premium
Regulatory role of transcription factor HBP1 in anticancer efficacy of EGFR inhibitor erlotinib in HNSCC
Author(s) -
Chan ChienYi,
Chang ChinMing,
Chen YuanHong,
Sheu Jim JinnChyuan,
Lin TzuYuan,
Huang ChunYin
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26346
Subject(s) - erlotinib , epidermal growth factor receptor , head and neck squamous cell carcinoma , cancer research , egfr inhibitors , erlotinib hydrochloride , transcription factor , chemistry , biology , medicine , cancer , head and neck cancer , biochemistry , gene
Background Epidermal growth factor receptor (EGFR) is often hyperactivated in head and neck squamous cell carcinoma (HNSCC); however, its downstream mediators are not fully identified. Here, we investigate the role of transcription factor HBP1 in the anticancer efficacy of EGFR inhibitor erlotinib in HNSCC. Methods The effect of erlotinib and HBP1 on cell proliferation and invasion was examined by flow cytometric analysis and a Matrigel invasion assay, respectively. Oral tumor specimens were used to evaluate the association between the expression level of EGFR and HBP1, and metastatic potential. Results Erlotinib caused cell growth arrest in the G1 phase and sluggish invasion with a concomitant increase in HBP1 and p27 expression. The erlotinib effect was attenuated upon HBP1 knockdown. Analysis of oral tumor specimens revealed that the low HBP1/high EGFR status can predict metastatic potential. Conclusions Our data support HBP1 as a crucial mediator of EGFR‐targeting inhibitors in HNSCC.